Get the Stockscreener App
3.38
2.11%
0.07
Pre-market:
3.45
0.07
+2.07%
Mannkind Corp stock is traded at $3.38, with a volume of 4.61M.
It is up +2.11% in the last 24 hours and up +23.36% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
See More
Previous Close:
$3.31
Open:
$3.32
24h Volume:
4.61M
Relative Volume:
0.70
Market Cap:
$1.04B
Revenue:
$348.97M
Net Income/Loss:
$5.86M
P/E Ratio:
201.19
EPS:
0.0168
Net Cash Flow:
$13.69M
1W Performance:
+9.39%
1M Performance:
+23.36%
6M Performance:
-32.80%
1Y Performance:
-19.91%
1-Day Range:
$3.32
$3.465
1-Week Range:
$2.93
$3.465
52-Week Range:
$2.23
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
3.38 | 1.02B | 348.97M | 5.86M | 13.69M | 0.0168 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Oct-10-25 | Initiated | Leerink Partners | Outperform |
| Jul-16-25 | Resumed | H.C. Wainwright | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-10-25 | Initiated | Wedbush | Outperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-10-23 | Initiated | Wedbush | Outperform |
| May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-24-19 | Initiated | Oppenheimer | Outperform |
| Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-14-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
| Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
| Oct-10-17 | Initiated | H.C. Wainwright | Buy |
| Oct-06-17 | Reiterated | Maxim Group | Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| May-10-16 | Reiterated | Piper Jaffray | Underweight |
| May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
| Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
| Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
| Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
| Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
| May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| May-11-15 | Reiterated | MLV & Co | Hold |
| Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
MannKind Corporation 8-K Filing Details Board Election Results and Company Information (May 2026) - Minichart
Director Michael A. Friedman awarded 82,781 MannKind (MNKD) restricted stock units - Stock Titan
MannKind director (MNKD) awarded stock and RSUs, updates holdings - Stock Titan
MannKind (MNKD) director Jennifer Grancio granted 82,781 restricted stock units - Stock Titan
MannKind (MNKD) awards 82,781 restricted stock units to director - Stock Titan
MannKind shareholders elect directors and approve proposals at annual meeting - Investing.com
MannKind (NASDAQ: MNKD) reports 2026 annual meeting voting results - Stock Titan
MNKD stock records biggest single-day gains in over 5 years, breaches a key technical milestone – what’s driving this rally? - MSN
MannKind Corp stock (US5638651064): inhaled insulin specialist draws attention after recent business - AD HOC NEWS
MannKind Corp stock (US5638651064): focus on Afrezza growth and partnership pipeline - AD HOC NEWS
MNKD Technical Analysis | Trend, Signals & Chart Patterns | MANNKIND CORP (NASDAQ:MNKD) - ChartMill
FY2026 EPS Estimates for MannKind Increased by HC Wainwright - MarketBeat
MannKind Corp. (MNKD) Reports Q1 2026 Total Revenues of $90.2M - Insider Monkey
MannKind Corp stock (US5638651064): respiratory drug specialist in focus after latest quarterly upda - AD HOC NEWS
5 Best NASDAQ Stocks Under $5 to Buy Right Now - Insider Monkey
MNKD (NASDAQ) amendment shows RSU resale filing via Morgan Stanley - Stock Titan
MannKind Corp stock (US5638651064): Biopharma innovator in inhaled therapies - AD HOC NEWS
MannKind EVP David Thomson sells $9,978 in company stock By Investing.com - Investing.com Australia
Mannkind director Steven Binder sells $55,732 MNKD stock - Investing.com
MannKind EVP David Thomson sells $9,978 in company stock - Investing.com India
Mannkind director Steven Binder sells $55,732 MNKD stock By Investing.com - Investing.com Nigeria
MANNKIND CORP (MNKD) officer has shares withheld to cover RSU taxes - Stock Titan
MannKind (MNKD) EVP trades shares under pre-set Rule 10b5-1 plan - Stock Titan
Wells Fargo Raises its Price Target on MannKind (MNKD) to $10 - Insider Monkey
[144] MANNKIND CORP SEC Filing - Stock Titan
10 Best Penny Stocks to Buy Before They Explode - Insider Monkey
State Street (NASDAQ: MNKD) holds 18.68M shares, 6.1% stake - Stock Titan
MannKind Corp stock (US5638651064): Q1 2026 earnings miss on EPS, revenue up 15% - AD HOC NEWS
The $59B Quiet Shift Reshaping How Patients Access Care - Benzinga
H.C. Wainwright and Wells Fargo Lift MannKind (MNKD) Price Targets - Insider Monkey
TradingKey - TradingKey
5 Best US Stocks Under $5 to Buy - Insider Monkey
MNKD Technical Analysis & Stock Price Forecast - Intellectia AI
MNKD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Q1 2026 MannKind Corp Earnings Call Transcript - GuruFocus
Wall Street Zen Downgrades MannKind (NASDAQ:MNKD) to Sell - MarketBeat
MannKind (MNKD) CEO clarifies 100,000-share Form 4 error in amendment - Stock Titan
MannKind (MNKD) Is Up 25.4% After Mixed Q1 Results and Expanded United Therapeutics Partnership – What's Changed - Yahoo Finance
MNKD Maintained by RBC Capital -- Price Target Raised to $4.75 - GuruFocus
MNKD Maintains Overweight Rating -- Price Target Raised to $10.0 - GuruFocus
MannKind Corporation (NASDAQ:MNKD) Q1 2026 Earnings Call Transcript - Insider Monkey
MannKind Q1 2026 slides: revenue up 15%, three catalysts ahead By Investing.com - Investing.com Canada
MannKind (NASDAQ:MNKD) Announces Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
MannKind Q1 Earnings Call Highlights - Yahoo Finance
MannKind Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):